英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

depopulation    音标拼音: [dɪp,ɑpjəl'eʃə] [d,ipɑpjəl'eʃə]
n. 人口减少

人口减少

depopulation
n 1: the condition of having reduced numbers of inhabitants (or
no inhabitants at all)

Depopulation \De*pop`u*la"tion\, n. [L. depopulatio pillaging:
cf. F. d['e]population depopulation.]
The act of depopulating, or condition of being depopulated;
destruction or explusion of inhabitants.
[1913 Webster]

The desolation and depopulation [of St.Quentin] were
now complete. --Motley.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
depopulation查看　depopulation　在百度字典中的解释百度英翻中〔查看〕
depopulation查看　depopulation　在Google字典中的解释Google英翻中〔查看〕
depopulation查看　depopulation　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo FDA Approval History Last updated by Judith Stewart, BPharm on Oct 9, 2025 FDA Approved: Yes (First approved September 28, 2018) Brand name: Libtayo Generic name: cemiplimab-rwlc Dosage form: Injection Company: Sanofi Treatment for: Squamous Cell Carcinoma, Basal Cell Carcinoma, Non Small Cell Lung Cancer Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    Libtayo® (cemiplimab-rwlc) Approved in the U S as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
  • FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy . . .
    Libtayo (cemiplimab-rwlc) approved in the U S as first and only immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) with a high risk of recurrence after surgery and
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation
  • FDA Approves Cemiplimab for Adjuvant Cutaneous Squamous Cell . . .
    The US FDA has approved the supplemental biologics license application (sBLA) for cemiplimab-rwlc (Libtayo) as adjuvant treatment in adults with high-risk cutaneous squamous cell carcinoma (CSCC) 1 The sBLA approval was based on an extensive review of data from the pivotal phase 3 C-POST study (NCT03969004) which demonstrated a statistically significant and clinically meaningful improvement
  • Cemiplimab Gains FDA Approval for Adjuvant High-Risk CSCC
    The FDA has approved adjuvant cemiplimab (Libtayo) for adults with high-risk cutaneous squamous-cell carcinoma after surgery and radiation
  • label - Food and Drug Administration
    During the treatment period ranging from 8 to 19 months in 5 clinical studies, the incidence of anti-cemiplimab-rwlc antibodies in LIBTAYO-treated patients was 2% (22 1029)
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide





中文字典-英文字典  2005-2009